Mutational analysis of primary and advanced chordoma tissue using next‐generation sequencing
Cancer · 15.08.2025 · 131 (16)
DOI: 10.1002/cncr.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 13.08.2025. Verfasst von Josh Chan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Chordoma, High-Throughput Nucleotide Sequencing, Mutation, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Chordomas are rare ectodermal bone malignancies derived from transformed notochordal remnants. Histologic variants include conventional (80%–90%), chondroid (5%–15%), and dedifferentiated (2%–8%). Because chordomas are relatively resistant to chemotherapy and radiotherapy, novel targeted agents are needed to expand treatment approaches and improve outcomes. This study analyzes the genomic landscape of chordoma and identifies potential pathogenic and druggable targets.
Methods
Eighty‐six tumor samples derived from chordoma patients treated at Massachusetts General Hospital, University of California, Los Angeles, and the University of Miami were included. Tumor specimens were sent for comprehensive molecular profiling using next‐generation sequencing. The most frequently mutated genes were identified and categorized by subtype, and microsatellite instability and programmed death ligand‐1 (PD‐L1) staining were assessed.
Results
Histologic subtypes included 70 conventional (81.4%), nine chondroid (10.5%), and seven dedifferentiated chordomas (8.1%). The most common mutations were cyclin‐dependent kinase inhibitor 2A/B ( CDKN2A/B ) (28 of 86, 33%), low‐density lipoprotein receptor‐related protein 1B (10 of 86, 12%), polybromo‐1 (9 of 86, 11%), and epidermal growth factor receptor ( EGFR ) (8 of 86, 9%). By subtype, CDKN2A/B mutation was most common in conventional chordoma (24 of 70, 34%), and chondroid chordoma (3 of 9, 33%). CDKN2A/B and EGFR mutations were most common in dedifferentiated chordoma (2/7, 29%). Microsatellite instability was not detected in seven of 69 (10.1%) samples. PD‐L1 staining of tumor and immune cells was scarce, with scores
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, Alberta, Canada.
- Department of Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, USA.
- Department of Orthopedics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
ORCID-Profile: Josh Chan, Joseph K Kendal, Zhenfeng Duan
Zitieren
APA
Chan, J., Kendal, J. K., Duan, Z., Ferreira, A., Samiei, A., Nelson, S. D., Singh, A., Lord, E. L., Crawford, B., Bernthal, N. M., & Hornicek, F. J. (2025). Mutational analysis of primary and advanced chordoma tissue using next‐generation sequencing. Cancer, 131(16). https://doi.org/10.1002/cncr.70033
Vancouver
Chan J, Kendal JK, Duan Z, Ferreira A, Samiei A, Nelson SD, et al. Mutational analysis of primary and advanced chordoma tissue using next‐generation sequencing. Cancer. 2025;131(16). doi:10.1002/cncr.70033
BibTeX
@article{Chan2025,
author = {Chan, Josh and Kendal, Joseph K and Duan, Zhenfeng and Ferreira, Al and Samiei, Alireza and Nelson, Scott D and Singh, Arun and Lord, Elizabeth L and Crawford, Brooke and Bernthal, Nicholas M and Hornicek, Francis J},
title = {Mutational analysis of primary and advanced chordoma tissue using next‐generation sequencing},
journal = {Cancer},
year = {2025},
volume = {131},
number = {16},
doi = {10.1002/cncr.70033}
}
EUVIMED